Why CRISPR Therapeutics Stock Is Trading Higher Today
CRISPR Therapeutics (NASDAQ:CRSP) shares are trading higher after the company and its partner Vertex Pharmaceuticals announced the EMA granted Priority Medicines designation to CTX001 for the treatment of transfusion-dependent beta thalassemia.
CTX001 is being investigated in two ongoing clinical trials as a potential one-time therapy for patients suffering from TDT and severe SCD.
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
The stock was 7.3% higher to $135.80 at the time of writing. The stock has a 52-week high of $220.20 and a 52-week low of $46.84.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.